Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinaciclib vs Ofatumumab in Refractory CLL
NCT01580228Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dinaciclib in chronic lymphocytic leukemia (CLL), sponsored by Merck & Co.. Started Aug 2012; status: completed.
02
Drugs
dinaciclib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01580228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01580228.